Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Palatin Technologies ( (PTN) ) has issued an announcement.
Palatin Technologies, Inc., a biopharmaceutical developer of melanocortin receptor–targeted drugs, announced on May 18, 2026 that it will voluntarily transfer the listing of its common stock from NYSE American to the Nasdaq Capital Market. The stock is expected to cease trading on NYSE American at the close on May 28, 2026 and begin trading on Nasdaq under the existing ticker PTN on May 29, 2026.
Management said joining Nasdaq’s biotechnology cohort should improve the visibility and liquidity of Palatin’s shares and broaden access to institutional investors, with no action required from existing shareholders. The move coincides with continued advancement of Palatin’s selective MC4R-based obesity programs for rare disorders, a timing that could help align the company’s capital markets profile with its late-preclinical and early-clinical pipeline milestones.
The most recent analyst rating on (PTN) stock is a Buy with a $47.50 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTN Stock Forecast page.
Spark’s Take on PTN Stock
According to Spark, TipRanks’ AI Analyst, PTN is a Neutral.
The score is held down primarily by weak financial fundamentals—ongoing losses, significant recurring cash burn, and reliance on financing—despite low debt. Technicals also remain bearish with the stock trading below major moving averages, only modestly tempered by oversold indicators. The earnings call added some support via improved quarterly performance and non-dilutive funding, but near-term runway and execution/competitive risks keep the overall profile cautious.
To see Spark’s full report on PTN stock, click here.
More about Palatin Technologies
Palatin Technologies, Inc. is a biopharmaceutical company focused on developing novel therapeutics targeting the melanocortin receptor system for diseases with significant unmet medical need and commercial potential. Its pipeline includes selective MC4R-based obesity programs, such as once-weekly injectable and oral peptide agonists aimed at rare obesity disorders like hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome, with an IND filing for its injectable candidate planned for late 2026 and a next-generation oral candidate targeted for early 2027.
The company’s development strategy emphasizes advancing potential best-in-class MC4R candidates with enhanced potency, improved tolerability and reduced off-target effects, including minimizing hyperpigmentation, to support safe, long-term use and eventual commercialization through partnerships with industry leaders. This positions Palatin within the competitive obesity therapeutics space, where differentiation on safety, tolerability and chronic use is increasingly critical for investor and partner interest.
Average Trading Volume: 16,151
Technical Sentiment Signal: Strong Sell
Current Market Cap: $25.64M
For an in-depth examination of PTN stock, go to TipRanks’ Overview page.